Kazia Therapeutics Ltd completes $25.2 million capital raising - (Proactive Investors via NewsPoints Desk)

  • Kazia Therapeutics has successfully completed the AUD $8.8 million retail component of its AUD $25.2-million entitlement offer of shares at 80 cents per new share, reported Proactive Investors.

  • Proceeds will go toward funding its participation in the pivotal GBM AGILE study for the investigational drug paxalisib in glioblastoma.

  • Kazia chairman Iain Ross said "we now move into the pivotal study for paxalisib in glioblastoma, placing us in the final stage of the drug development process and on a direct path to commercialization."

To read more NewsPoints articles, click here.

Reference Articles